Latest news

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement

License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology   DUBLIN, Ireland and Coralville, Iowa, 17 August 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Cellular Engineering Technologies (CET), a biotechnology company specializing in cell manufacturing and contract research services, today announced a non-exclusive license agreement granting CET access to ERS Genomics’ CRISPR/Cas9 patent portfolio. With its expertise in cell and tissue engineering, CET supports research organizations at the interface of stem cell research and preclinical

Read more
News

Top news